All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Accepts sBLA for Polatuzumab Vedotin Plus R-CHP in Untreated DLBCL

August 16th 2022

The FDA has accepted a supplemental biologics license application for the combination of polatuzumab vedotin and R-CHP as a treatment for patients with previously untreated diffuse large B-cell lymphoma.

FDA Grants Priority Review to Olaparib/Abiraterone Regimen in Metastatic Castration-Resistant Prostate Cancer

August 16th 2022

The FDA has granted priority review to a supplemental new drug application seeking the approval of olaparib in combination with abiraterone acetate and prednisone or prednisolone in adult patients with metastatic castration-resistant prostate cancer.

GI Cancer Expert Sets Sights on the Next Generation

August 16th 2022

At the start of his career, Weijing Sun, MD, FACP, was motivated to explore potential new treatments for gastrointestinal malignancies, and is now an internationally known GI cancer expert.

INBRX-109 Granted Orphan Drug Designation in Europe for Chondrosarcoma

August 16th 2022

The European Commission has granted an orphan medicinal product designation to INBRX-109 for use as a potential therapeutic option in patients with chondrosarcoma.

Subcutaneous Epcoritamab Plus R-DHAX/C Shows Promising Preliminary Activity in ASCT-Eligible, R/R DLBCL

August 15th 2022

Raul Cordoba, MD, PhD, discussed the efficacy and safety findings from cohort 4 of the EPCORE NHL-2 trial, the benefits observed with epcoritamab monotherapy in patients who did not proceed to transplant, and what the addition of epcoritamab to R-DHAX/C could mean for patients with relapsed/refractory DLBCL.

Sacituzumab Govitecan Prolongs OS in Heavily Pretreated HR+ Breast Cancer

August 15th 2022

Sacituzumab govitecan elicited a statistically significant and clinically meaningful improvement in overall survival vs standard chemotherapy in patients with hormone receptor–positive, HER2-negative breast cancer who received prior treatment with endocrine therapy, CDK4/6 inhibitors, and 2 to 4 lines of chemotherapy, according to findings from the second interim analysis of the phase 3 TROPiCS-02 trial.

Belzutifan Generates Promising Responses and Safety in Advanced Stage Clear Cell RCC

August 15th 2022

Eric Jonasch, MD, discusses the efficacy and safety of belzutifan observed in the LITESPARK-001 trial for patients with advanced clear cell RCC and the next steps for investigating belzutifan in this patient population.

Teclistamab Demonstrates Durable Response Rates in BCMA-Pretreated Multiple Myeloma

August 15th 2022

Saad Z. Usmani, MD, MBA, FACP, discusses key efficacy findings that support the use of teclistamab in patients with relapsed/refractory multiple myeloma who have had prior exposure to BCMA-targeted agents.

Canakinumab Fails to Meet DFS End Point in Resected NSCLC

August 15th 2022

The anti–interleukin-1β monoclonal antibody canakinumab did not generate a disease-free survival benefit vs placebo in adult patients with stages II to IIIA and IIIB completely resected non–small cell lung cancer, failing to meet the primary end point of the phase 3 CANOPY-A trial.

Trastuzumab Deruxtecan Improves PFS, OS in T-DM1–Pretreated HER2+ Metastatic Breast Cancer

August 15th 2022

Trastuzumab deruxtecan led to a statistically significant improvement in progression-free survival and overall survival vs treatment with physician’s choice in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

American Oncology Network Names Karen Pilley Chief Revenue Cycle Officer

August 15th 2022

American Oncology Network, LLC, a high-growth medical oncology provider with a focus on supporting the long-term viability of cancer treatment in community-based settings, recently announced the appointment of Karen Pilley, as the organization’s Chief Revenue Cycle Officer.

Tumor Agnostic Approval Targets BRAF V600E–Mutant Disease

August 15th 2022

Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.

Unique Aspects of Maintenance Therapy in Oncology Require Careful Consideration

August 14th 2022

Maurie Markman, MD, discusses maintenance therapy and how it differs from other strategies in cancer care.

Nivolumab/Ipilimumab Combo Provides Long-Term Survival Benefit in Advanced HCC After Sorafenib

August 13th 2022

The dual immunotherapy combination comprised of nivolumab given at 1 mg/kg and ipilimumab given at 3 mg/kg provided durable responses and long-term survival benefit in patients with advanced hepatocellular carcinoma following treatment with sorafenib.

Darolutamide Tablets Usher in New Standard of Care in mHSPC

August 12th 2022

Jacob Berchuck, MD, discusses the effect of the approval of darolutamide tablets on the standard of care for patients with metastatic hormone sensitive prostate cancer.

Expanded Efficacy Data Underscore Nivolumab Combinations Role as Standard of Care for ESCC

August 12th 2022

Recent data highlight the value of the newly approved indications for nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma.

Single-Agent Pembrolizumab Maintains Survival Benefit in Sorafenib-Pretreated Advanced HCC

August 12th 2022

Pembrolizumab monotherapy continued to demonstrate durable antitumor activity with promising overall survival in patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib, according to updated data from cohort 1 of the phase 2 KEYNOTE-224 trial.

Panitumumab Plus mFOLFOX6 Improves Survival in RAS Wild-Type mCRC

August 12th 2022

Treatment with frontline panitumumab and mFOLFOX6 led to a significant improvement in overall survival, plus higher response rates and R0 resection rates, compared with bevacizumab and mFOLFOX6 in patients with RAS wild-type metastatic colorectal cancer.

Adagrasib Elicits Responses in KRAS G12C–Mutant NSCLC

August 12th 2022

Joshua K. Sabari, MD, discusses the significance of adagrasib as an agent with favorable central nervous system penetration and importance of performing next-generation sequencing in all patients with non–small cell lung cancer to detect KRAS G12C mutations.

Targeted Agents Continue to Emerge for HER2+ GI Cancers

August 12th 2022

After HER2 was established as an actionable target in gastric cancer, its amplification has become a key biomarker of interest for other gastrointestinal cancers.